Analysis shows Swiss biotech index outshines Nasdaq counterpart, but coronavirus challenges are universal

In 2004, the Swiss Stock Exchange spawned its biotech index — the Swiss Bio+Medtech Index (SXI) — as the life sciences sector, headlined by large successful biopharma companies Roche and Novartis, took center stage. In the last five years through January 2020, SXI has produced returns of 59%, outperforming both the Swiss Performance Index (31%) and the NASDAQ Biotechnology Index (35%), a new analysis shows.